In all NSCLC patients who received platinum-based chemotherapy/immunotherapy, no significant difference in PFS and OS was observed between DDR-positive and DDR-negative group (Fig. 4C and D). The gene discussed is DDR1; the disease is non-small cell lung carcinoma.